CooperCompanies completed the strategic review it announced in December 2025 and said its Board unanimously decided that shareholders would be better served by retaining CooperSurgical rather than pursuing a sale at this time. The review considered the company’s portfolio, capital allocation, strategic alternatives, corporate structure, leadership, operations and strategy. The Board said recent developments involving a competitive entrant in the non-hormonal IUD market and the company’s fertility litigation settlement contributed to a valuation disconnect, with offers received judged not to be in shareholders’ best interests. The company repurchased $445 million of shares during the current fiscal year and increased its share repurchase authorization from $2 billion to $3 billion. CooperCompanies also added two independent directors with healthcare, operational and capital-allocation expertise, expanded CooperVision’s global sales and marketing organization, pursued cost and efficiency programs, revised inventory and logistics processes, and accelerated new product introductions. The Vision Centre, CooperVision’s global research and development innovation hub, opened on September 23, 2026. CooperCompanies said CooperVision investments in commercial capabilities, innovation and organic growth will remain its top priority, while CooperSurgical will focus on fertility growth, operating performance and organic expansion. The company also announced third-quarter 2026 results separately and scheduled a webcast at approximately 5:00 PM ET.